pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 40 Non-oncology: 24
Oncology: 16
Under Consideration for Negotiation 18 Non-oncology: 13
Oncology: 5
Completed Negotiations 778 With Letter of Intent: 673
Without agreement: 105
Negotiations That Were Not Pursued 108

pCPA activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement letters issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Niopeg Nora Pharma Inc. To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drug.
Cosentyx Novartis Pharmaceuticals Canada Inc. Hidradenitis Suppurativa
Breyanzi Bristol Myers Squibb Canada Inc. Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL), and DLBCL arising from follicular lymphoma, who have refractory di
Crysvita Kyowa Kirin Canada, Inc. X-Linked Hypophosphatemia
Padcev Pfizer Canada ULC In combination with pembrolizumab, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC.
Keytruda Merck Canada Inc. In combination with enfortumab vedotin, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC.

Negotiations completed in the last four weeks with a letter of intent

Brand Name Manufacturer Indication Engagement Date Close Date
Tyenne Fresenius Kabi Canada Ltd. Multiple Indications
Remdantry Celltrion Healthcare Canada Ltd. Multiple Indications
Epidiolex Jazz Pharmaceuticals Canada Inc. Seizures associated with Tuberous Sclerosis Complex (TSC)
Epidiolex Jazz Pharmaceuticals Canada Inc. Lennox-Gastaut Syndrome (LGS)
Epidiolex Jazz Pharmaceuticals Canada Inc. Dravet Syndrome (DS)
Stoboclo Celltrion Healthcare Canada Ltd. Multiple Indications
Osenvelt Celltrion Healthcare Canada Ltd. Multiple Indications
Libtayo Regeneron Non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, first-line treatment of adult patients who have locally advanced
Libtayo Regeneron in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or c‐ROS oncogene 1 (ROS1
Libtayo Regeneron For the treatment of patients with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor
Axberi/Axberi HP Baxter Corporation Thrombosis and cardiovascular conditions (prevention or treatment)
Ixifi Pfizer Canada ULC Multiple Indications
Opdivo-Yervoy Bristol Myers Squibb Canada Inc. ​In combination, for the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma when patients progress during or within 6 months of adjuvant PD-1 therapy.
Opdivo-Yervoy Bristol Myers Squibb Canada Inc. In neoadjuvant setting for resectable stage III melanoma.
Keytruda Merck Canada Inc. as monotherapy for the adjuvant treatment of adult patients with Stage IB (T2a 4 cm), II, or IIIA NSCLC, and with PD-L1 tumor proportion score (TPS) less than 50% who have undergone complete resection and platinum-based chemotherapy.
Keytruda Merck Canada Inc. As monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors

Negotiations completed in the last four weeks without agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA decided not to pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks